{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:54:49Z","timestamp":1793858089773,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clinthera.2020.05.021","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T01:59:04Z","timestamp":1595642344000},"page":"1452-1466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit\/Hyperactivity Disorder in School-age Children"],"prefix":"10.1016","volume":"42","author":[{"given":"Azmi","family":"Nasser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye","family":"Liranso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyin","family":"Adewole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Chowdhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita Joshi","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-5782","authenticated-orcid":false,"given":"Robert L.","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.05.021_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1471","article-title":"Twenty-year trends in diagnosed attention-deficit\/hyperactivity disorder among US children and adolescents, 1997-2016","volume":"1","author":"Xu","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2020.05.021_bib2","first-page":"66","article-title":"The diagnosis and management of attention-deficit\/hyperactivity disorder in pediatric patients","volume":"3","author":"Adesman","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatr"},{"key":"10.1016\/j.clinthera.2020.05.021_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.clinthera.2020.05.021_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1087054714566076","article-title":"Long-term outcomes of ADHD: academic achievement and performance","volume":"24","author":"Arnold","year":"2020","journal-title":"J\u00a0Atten Disord"},{"key":"10.1016\/j.clinthera.2020.05.021_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12888-015-0624-5","article-title":"Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): a multinational cross-sectional study in Europe","volume":"15","author":"Deberdt","year":"2015","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2020.05.021_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12254","article-title":"Lost in transition: a review of the unmet need of patients with attention deficit\/hyperactivity disorder transitioning to adulthood","volume":"9","author":"Treuer","year":"2017","journal-title":"Asia Pac Psychiatr"},{"key":"10.1016\/j.clinthera.2020.05.021_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Aacap Work Group on Quality Issues: practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"key":"10.1016\/j.clinthera.2020.05.021_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","article-title":"ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"128","author":"Wolraich","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2020.05.021_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/108705470000300403","article-title":"Methyiphenidate vs. amphetamine: comparative review","volume":"3","author":"Arnold","year":"2000","journal-title":"J\u00a0Atten Disord"},{"key":"10.1016\/j.clinthera.2020.05.021_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.clinthera.2020.05.021_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.2016.1147558","article-title":"Current investigational drugs for the treatment of attention-deficit\/hyperactivity disorder","volume":"25","author":"Childress","year":"2016","journal-title":"Expet Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2020.05.021_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-1781(91)90126-A","article-title":"Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?","volume":"36","author":"Elia","year":"1991","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.clinthera.2020.05.021_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/cap.2011.0018","article-title":"Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts","volume":"21","author":"Stein","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.05.021_bib14","series-title":"Methylphenidate HCl Extended-Release Tablets CII, Prescribing Information","author":"CONCERTA\u00ae","year":"2013"},{"key":"10.1016\/j.clinthera.2020.05.021_bib15","series-title":"Lisdexamfetamine Dimesylate Capsules and Chewable Tablets, for Oral Use, CII, Prescribing Information","author":"VYVANSE\u00ae","year":"2017"},{"key":"10.1016\/j.clinthera.2020.05.021_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/7854_2015_426","article-title":"Misuse of methylphenidate","volume":"34","author":"Clemow","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.clinthera.2020.05.021_bib17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","article-title":"Psychosis with methylphenidate or amphetamine in patients with ADHD","volume":"380","author":"Moran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.021_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40271-015-0112-5","article-title":"Systematic review of patients' and parents' preferences for ADHD treatment options and processes of care","volume":"8","author":"Schatz","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.clinthera.2020.05.021_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4088\/JCP.08m04902pur","article-title":"A\u00a0comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes","volume":"71","author":"Faraone","year":"2010","journal-title":"J\u00a0Clin Psychiatr"},{"key":"10.1016\/j.clinthera.2020.05.021_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.clinthera.2020.05.021_bib21","series-title":"Lilly USA","article-title":"Atomoxetine, CAPSULES for oral use, prescribing information Indianapolis","year":"2017"},{"key":"10.1016\/j.clinthera.2020.05.021_bib22","series-title":"Guanfacine) Extended-Release Tablets, for Oral Use, Prescribing Information","year":"2017"},{"key":"10.1016\/j.clinthera.2020.05.021_bib23","series-title":"Clonidine Hydrochloride Extended-Release Tablets, Oral, Prescribing Information","author":"KAPVAY\u00ae","year":"2010"},{"key":"10.1016\/j.clinthera.2020.05.021_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.021_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1139\/y76-069","article-title":"Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities","volume":"54","author":"Lippman","year":"1976","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.021_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1087054719836159","article-title":"A\u00a0Phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD","volume":"24","author":"Johnson","year":"2020","journal-title":"J\u00a0Atten Disord"},{"key":"10.1016\/j.clinthera.2020.05.021_bib27","series-title":"ADHD Rating Scale\u20145 for Children and Adolescents Checklists, Norms, and Clinical Interpretation","first-page":"1","article-title":"Introduction to the ADHD rating scales","author":"DuPaul","year":"2016"},{"key":"10.1016\/j.clinthera.2020.05.021_bib28","series-title":"ECDEU Assessment Manual for Psychopharmacology (Revised, 1976 Ed.","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.clinthera.2020.05.021_bib29","series-title":"Conners Rating Scales","author":"Conners","year":"2008"},{"key":"10.1016\/j.clinthera.2020.05.021_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12955-015-0379-1","article-title":"Psychometric validation of the Weiss functional impairment rating scale-parent report form in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"13","author":"Gajria","year":"2015","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clinthera.2020.05.021_bib31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s11136-017-1514-8","article-title":"The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis","volume":"26","author":"Thompson","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2020.05.021_bib32","series-title":"Parenting Stress Index, 3rd ed.: Professional Manual","author":"Abidin","year":"1995"},{"key":"10.1016\/j.clinthera.2020.05.021_bib33","series-title":"Multiple Comparisons and Multiple Tests Using SAS\u00ae","author":"Westfall","year":"1999"},{"key":"10.1016\/j.clinthera.2020.05.021_bib34","first-page":"44","article-title":"Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD","volume":"17","author":"Goodman","year":"2010","journal-title":"Prim Psychiatr"},{"key":"10.1016\/j.clinthera.2020.05.021_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0924-977X(03)00047-6","article-title":"Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention","volume":"13","author":"Buitelaar","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2020.05.021_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112361","article-title":"Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects","volume":"9","author":"Azab","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.05.021_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/104454603322163853","article-title":"Stimulant rebound: how common is it and what does it mean?","volume":"13","author":"Carlson","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clinthera.2020.05.021_bib38","first-page":"192","article-title":"A\u00a0review of pharmacological management of attention-deficit\/hyperactivity disorder","volume":"21","author":"Briars","year":"2016","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2020.05.021_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cap.2006.0141","article-title":"Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit\/hyperactivity disorder","volume":"18","author":"Cox","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2020.05.021_bib40","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1136\/adc.2004.059352","article-title":"Managing attention deficit\/hyperactivity disorder: unmet needs and future directions","volume":"90","author":"Steer","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinthera.2020.05.021_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881114542453","article-title":"Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials","volume":"28","author":"Asherson","year":"2014","journal-title":"J\u00a0Psychopharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:18Z","timestamp":1758963198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0149291820302836"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit\/Hyperactivity Disorder in School-age Children","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}